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To the Editor
The severe acute respiratory syndrome coro‑
navirus 2 (SARS‑CoV‑2), causing coronavirus 
disease 2019 (COVID‑19), arrived in Belgium 
early February 2020 [1]. This was the start 
of an epidemic that, by May 2nd, 2021, would 
be responsible for 993,434 confirmed cases; 
70,384 hospitalisations and 24,258 fatalities [2]. 
After more than one year of research into the 
disease and its causative agent, a lot of progress 
has been made in management and treatment 
of COVID‑19 [3]. As of December 21st, 2020, 
the Belgian Federal Agency for Medicines and 
Healthcare products (FAHMP) reported that 
32 clinical drug trials, 6 clinical vaccine trials 
and 5 clinical studies with medical devices 
and/or in vitro diagnostics were authorized [4]. 
Continued research efforts are essential to tack‑
ling the persisting pandemic.
 To obtain an insight into the clinical studies 
already performed in Belgium, the clinical trials 
database of FAHMP was searched for “covid‑19”. 
To identify additional studies not involving inves‑
tigational medicinal products (IMPs), the clinical‑
trials.gov database was searched for “COVID‑19”, 
“COVID” and “SARS‑CoV‑2”. The results were 
filtered for studies in Belgium that were complet‑
ed, suspended or terminated.
Thirty‑three unique studies were retrieved 
from the FAHMP register (Supplementary materi‑
als, Table S1). Of these studies, 23 (69.70%) were 
being conducted at multiple sites in Belgium. 
This means that in a large majority of the stud‑
ies, there was a cooperation between different 
institutions. Monocentric studies were often 
carried out in centres with specific expertise. 
Twenty‑six (78.79%) studies utilized randomi‑
sation. Despite being only part of study design, 
this observation suggests that the urgency by 
which knowledge about COVID‑19 is needed, 
did not negatively impact the scientific rigor of 
the research performed. 
The number of studies per phase of devel‑
opment studies are shown in Figure 1. Five of 
the extracted studies (15,15%) were in phase 
I (human pharmacology). Most of these studies 
investigated the safety and immunogenicity of 
vaccine candidates. Nine (27.27%) studies were 
only in phase II (therapeutic exploratory). These 
studies investigated a wide variety of treatment 
strategies to tackle COVID‑19, ranging from anti‑
viral drugs to cell therapy. Phase III (therapeutic 
confirmatory) studies accounted for 6 (18.18%) of 
the total number of studies. These studies looked 
into the safety and efficacy of several treatments 
for disease management and prevention. Five 
(15.15%) studies were described being both phase 
II & III. Finally, 8 studies were in phase IV (ther‑
apeutic use). Based on these observations, it can 
be stated that COVID‑19 research in all phases of 
the development process is being conducted in 
the Belgian territory.
Twenty‑eight completed or terminated stud‑
ies were conducted in Belgium according to 
the clinicaltrials.gov database (Supplemen‑
tary materials, Table S2). Completed studies 
numbered 25 (89.29%) and terminated studies 
3 (10.71%). The three terminated studies in‑
vestigated hydroxychloroquine as a treatment, 
a COVID‑19 vaccine and the performance of 
three sampling methods. Unfortunately, none 
of the completed studies had results available. 
From the identified studies, it is clear that a lot 
of different research interventions have been 
used for COVID‑19 research, including ques‑
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tionnaires and drug treatment. This is linked to 
the wide range of research topics of the studies, 
which ranged from discontinuation of fertility 
treatment to quality of life of oncology patients 
during the pandemic. A lot of aspects besides the 
purely medical and virological questions about 
the pandemic are being investigated.
Eleven (39.28%) of the studies were interven‑
tional while 17 were observational (60.71%). This 
means that several types of study design are used 
to investigate the COVD‑19 pandemic.
 In general, it is clear that a lot of research on 
COVID‑19 has been conducted in Belgium. The 
studies are diverse in scope and methods. A more 
comprehensive analysis of the research conduct‑
ed, could provide directions for further research. 
Additionally, systematic reviews and meta‑analy‑
ses could synthesize the different studies already 
conducted. 
Figure 1. Number of studies approved by Federal Agency for Medicines and healthcare products (FAMHP) per phase
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